Screening for safe opening of universities under

Omicron and Delta variants of COVID-19: ²

When less is more ³

Marie Jeanne Rabil1,*,@**, Sait Tunc**1,@**, Douglas R. Bish**2,+**, and Ebru K. Bish**2,+

¹Virginia Polytechnic Institute and State University, Grado Department of Industrial and Systems Engineering, Blacksburg, 24061, United States of America ⁶ ²The University of Alabama, Department of Information Systems, Statistics, and Management Science, Culverhouse College of Business, Tuscaloosa, 35487, United States of America ⁸ $\displaystyle{\raisebox{0.6ex}{\scriptsize{*}}}$ mariejeanne@vt.edu $^{\omega}$ these authors contributed equally to this work 10 + these authors contributed equally to this work ¹¹

ABSTRACT ¹²

As new COVID-19 variants emerge, and disease and population characteristics change, screening strategies may also need to change. We develop screening guidelines for the safe opening of college campuses, considering COVID-19 infections/hospitalizations/deaths; peak daily hospitalizations; and the tests required. Our compartmental model simulates disease spread on a college campus under co-circulating variants with different disease dynamics, considering: (i) the heterogeneity in disease transmission and outcomes for faculty/staff and students based on vaccination status and level of natural immunity; and (ii) variant- and dose-dependent vaccine efficacy. Using the Spring 2022 academic semester as a case study, we study various routine screening strategies, and find that screening the faculty/staff less frequently than the students, and/or the boosted and vaccinated less frequently than the unvaccinated, may avert a higher number of infections per test, compared to universal screening of the entire population at a common frequency. We also discuss key policy issues, including the need to revisit the mitigation objective over time, effective strategies that are informed by booster coverage, and if and when screening alone can compensate for low booster coverage.

Introduction ¹⁴

Two years into the pandemic, and, COVID-19, through emerging variants, continues to pose a threat to in-person education in ¹⁵ academic institutions. Once again, universities and colleges are facing an abundance of COVID-19 cases on their campuses [\[1\]](#page-10-0), ¹⁶ and are finding themselves in a position to reformulate/reoptimize their infection mitigation strategies (e.g., vaccination mandates, 17

13

4

routine screening, face masking, and social distancing policies, hybrid learning practices), to adapt to the characteristics of the 18 new Delta and Omicron variants, with an eye on future variants yet to come. A continuous reformulation of infection mitigation ¹⁹ strategies will remain essential as the pandemic continues to evolve with new virus variants, and as the current interventions 20 (vaccines, testing kits, masks), their availability, and efficacy continue to change. With COVID-19 vaccination and testing kits ²¹ already developed, the current challenges for effective mitigation differ from those faced at the beginning of the pandemic. 22 Now the mitigation strategies need to account for new virus variants with different transmission and disease dynamics [\[2,](#page-10-1) [3\]](#page-11-0), 23 and vaccine effectiveness that is not only imperfect and decaying over time $[4]$, but is also variant-dependent.

Indeed, as the year 2021 came to an end, the then-dominating Delta variant of the virus started to be replaced with the \approx emerging Omicron variant, which, by the beginning of 2022, has become the primary variant that was causing more than 70% 26 of all COVID-19 infections in the United States (U.S.) [\[5\]](#page-11-2). From an intervention strategy perspective, there are important γ differences between the Delta and Omicron variants. While the Omicron variant spreads easier than the Delta variant (even 28 among the vaccinated), it is less likely to cause severe illness [\[6\]](#page-11-3), especially in vaccinated and boosted populations [\[7\]](#page-11-4). Further, 29 while this new period of the pandemic is marked by wide availability of the vaccine, it is also marked by vaccine hesitancy in ³⁰ certain groups [\[8\]](#page-11-5), and, once more, by the scarcity of the testing resources [\[9\]](#page-11-6). As a result, there is an ongoing need to utilize $\frac{31}{2}$ the limited testing resources in the most effective and efficient way for routine screening of the asymptomatic individuals, $\frac{32}{2}$ who can still transmit the disease [\[10\]](#page-11-7). Motivated by these observations, in this paper we build and analyze a compartmental ³³ model, to develop optimal *customized screening* strategies for college/university campuses, considering the characteristics of ³⁴ the campus population (e.g., vaccine intake rates, campus size, age distribution), and of the disease (e.g., circulating variant(s) $\frac{1}{35}$ and their transmission and disease characteristics, and vaccine effectiveness). 36

The literature on screening and vaccination for infectious diseases is vast, and growing, thanks to the pandemic. We refer σ the interested reader to the many references in $[11, 12, 13, 14, 15, 16]$ $[11, 12, 13, 14, 15, 16]$ $[11, 12, 13, 14, 15, 16]$ $[11, 12, 13, 14, 15, 16]$ $[11, 12, 13, 14, 15, 16]$ $[11, 12, 13, 14, 15, 16]$ $[11, 12, 13, 14, 15, 16]$ $[11, 12, 13, 14, 15, 16]$ $[11, 12, 13, 14, 15, 16]$ $[11, 12, 13, 14, 15, 16]$ $[11, 12, 13, 14, 15, 16]$ for screening related work, in $[17, 18, 19, 20, 21, 22,$ $[17, 18, 19, 20, 21, 22,$ $[17, 18, 19, 20, 21, 22,$ $[17, 18, 19, 20, 21, 22,$ $[17, 18, 19, 20, 21, 22,$ $[17, 18, 19, 20, 21, 22,$ $[17, 18, 19, 20, 21, 22,$ $[17, 18, 19, 20, 21, 22,$ $[17, 18, 19, 20, 21, 22,$ $[17, 18, 19, 20, 21, 22,$ $[17, 18, 19, 20, 21, 22,$ 38 [23,](#page-12-6) [24,](#page-12-7) [25,](#page-12-8) [26,](#page-12-9) [27\]](#page-12-10) for vaccination related work, and in [\[28,](#page-12-11) [29,](#page-12-12) [30\]](#page-12-13) for screening and vaccination related work; and simply ³⁹ discuss the more recent, Omicron-related works here. The academic literature related to Omicron is still quite limited: [\[31\]](#page-13-0) ⁴⁰ develops a compartmental model to predict various outcome metrics related to the Omicron variant under different transmission ⁴¹ and severity scenarios, while [\[32\]](#page-13-1) develops a compartmental model that considers vaccination (including boosters), waning 42 immunity from the vaccine, and different COVID-19 variants (including Omicron), in order to estimate the reduction in $\frac{43}{45}$ transmission rates, and its effect on daily infections, in response to various government policies in Korea. [\[33\]](#page-13-2) develops a 44 compartmental model to investigate the impact of vaccination coverage on different outcome metrics under the Omicron variant ⁴⁵ and a less transmissible variant. Importantly, neither work [\[31,](#page-13-0) [32,](#page-13-1) [33\]](#page-13-2) models and studies screening strategies, which is the $\frac{46}{10}$ main focus of our paper. 47

Specifically, we contribute to this stream of literature by building an extended compartmental model to study routine ⁴⁸ screening strategies, which may be customized based on the vaccination status and/or the demographics of campus residents. 49 To this end, we model each individual's vaccination status using three categories, unvaccinated, fully vaccinated (hereafter, so

"vaccinated"), and boosted; and consider faculty/staff (hereafter, "faculty") versus student groups. This customization allows us $_{51}$ to consider a wide range of routine screening policies, ranging from *universal* (i.e., screening all campus residents with the ₅₂ same frequency), to *partially customized* (i.e., screening only selected vaccination status, with a common frequency), to *fully* 53 *customized* (i.e., further customizing the screening frequency for each group selected for screening). In addition to campus ⁵⁴ demographics, our compartmental model also accounts for vaccination coverage (proportion vaccinated/proportion boosted), ss two circulating variants (Delta and Omicron), and less-than-perfect screening compliance of the campus residents. ⁵⁶

We also model imperfect vaccine effectiveness, with effectiveness values that depend on both the variant (Delta versus 57 Omicron) and the vaccination status (vaccinated versus boosted); and a time-dependent disease transmission rate, which varies ⁵⁸ as the proportion of the infectious population changes over time. Because two variants may be circulating at the same time, ₅₉ vaccine effectiveness, infection transmission rates, and other disease characteristics now become conditional on which variant 60 each individual is exposed to. $\frac{61}{100}$

These aspects necessitate new modeling approaches in our compartmental model. Using this model, we compare the ϵ_{eq} efficiency and effectiveness of various routine screening strategies based on multiple criteria, including the number of infections/hospitalizations/deaths, and peak infections/hospitalizations. Our model allows a college to conduct a comparative 64 study of various screening strategies, so as to develop their optimal strategy based on total and peak case numbers the college is ⁶⁵ able to cope with.

Results ⁶⁷

The study setting is a hypothetical college with a population of $24,000$ ($22,500$ students and $2,500$ faculty/staff), during an 80-day 68 Spring 2022 academic semester that starts in January 2022. Our SEIR (Susceptible, Exposed, Infectious, Removed) framework 69 simulates COVID-19 infection spread, considering different levels of vaccine-induced immunity and natural immunity, and a τ variety of protective and preventative interventions, including routine screening of the asymptomatic population, vaccination, $\frac{71}{20}$ face masking, symptomatic testing, and isolation of the test-positive cases. Another key aspect of this framework is the 72 modeling that the two variants, Delta and Omicron, can be in circulation simultaneously, with parameter ω_0 representing the τ_3 proportion (in %) of all COVID-19 infections caused by Omicron, and the remaining $1-\omega_0$ representing the proportion caused τ_4 by Delta. We explicitly model that vaccine effectiveness, infection transmission, and disease characteristics are conditional on π which variant each individual is exposed to. As the initial conditions, some individuals arrive on campus as fully vaccinated or boosted; we also introduce a number of undetected, asymptotic SARS-CoV-2 infections to the campus at the outset $(135 \quad \pi$ students and 9 faculty members, representing 0.6% of each group).

Screening Strategy 79

We first focus on routine screening that is either universal, or customizes only the screening population (Table [1\)](#page-21-0), and postpone $\frac{80}{100}$ the discussion of screening frequency customization until the next section. The base case considers 75% screening compliance, $\frac{81}{100}$ and total vaccination coverage of 82% (64% boosted, 18% vaccinated), with 18% unvaccinated at the start of the semester $\frac{82}{10}$

(Table [2\)](#page-21-1). With regards to variant prevalences, we discuss two important cases that represent the pandemic progression: ⁸³ ω ^{α} = 50%, where both Omicron and Delta variants are in circulation in similar rates, which may represent the U.S. during late ϵ December 2021 [\[34\]](#page-13-3); and $\omega_0 = 95\%$, where Omicron takes over as the predominant variant, which was the case in the U.S. ⁸⁵ starting in early January 2022 [\[35\]](#page-13-4).

Impact of Variant Breakdown ⁸⁷

We study the impact of pandemic progression (i.e., the transition of the dominant variant from Delta to Omicron) on the ⁸⁸ performance of screening strategies, under 82% total vaccination coverage (with 64% of the population boosted and 18% vaccinated), and 18% unvaccinated. When both Delta and Omicron variants are in circulation at similar rates ($\omega_0 = 50\%$, see ω_0 Supplementary Table 4), universal screening every 1/2/14 days results in 1,012/4,058/15,458 total infections, and 31/31/142 peak daily infections, respectively. If the boosted individuals are excluded from screening, the 1/2/14-day screening strategies 92 yield 7,967/12,168/16,741 total infections, and 45/81/159 peak daily infections, respectively. The strategy that averts the highest 93 number of infections per test is screening the unvaccinated only every 14 days, with 31.6 infections averted per 1,000 tests over 94 no screening (see Fig. [1\(](#page-16-0)a)); furthermore, this strategy also provides the highest reduction in peak infections per test, reducing $\frac{1}{5}$ the peak by 0.9 infections per 1,000 tests over no screening (see Fig. [2\(](#page-17-0)a)).

Under $\omega_0 = 50\%$, the strategy that averts the highest number of infections per test depends on the booster coverage. When $\frac{97}{97}$ 64% of the population is boosted and 18% is vaccinated, if the screening frequency of the unvaccinated is set to every $1/2/3/7/14$ ⁹⁸ days, the strategy that averts the highest number of infections per test is screening the unvaccinated and vaccinated every 1/2 $\frac{99}{2}$ days, and screening the unvaccinated only every $3/7/14$ days, averting $23.2/27.5/29/31/31.6$ infections per 1,000 tests (see 100 Fig. [1\(](#page-16-0)a)), respectively, whereas the strategy that averts the highest number of infections per test with 38% boosted and 44% $_{101}$ vaccinated, is screening the vaccinated and unvaccinated every 1/2/3/7 days and screening the unvaccinated only every 14 days, 102 averting 17.6/20.19/20.23/19.3/19.5 infections per 1,000 tests (see Fig. [1\(](#page-16-0)b)), respectively. ¹⁰³

When Omicron is the predominant variant ($\omega_Q = 95\%$, see Supplementary Table 5), universal screening every $1/2/14$ ¹⁰⁴ days results in 8,568/17,327/22,512 total infections, and 61/222/465 peak daily infections, respectively. When screening 105 excludes boosted individuals, 1/2/14-day screening yields 21,578/22,111/22,820 total infections, and 312/380/487 peak daily 106 infections, respectively. Under this scenario, the strategy that averts the highest number of infections per test is the daily 107 universal screening, averting 11.9 infections per 1,000 tests (see Fig. [1\(](#page-16-0)c)), whereas the strategy that provides the highest $_{108}$ reduction in peak infections per test is screening the unvaccinated every 3 days, which reduces the peak by 1.09 infections per 109 1,000 tests (see Fig. [2\(](#page-17-0)c)). 1000 tests (see Fig. 2(c)).

Under $\omega_0 = 95\%$, if the screening frequency of the unvaccinated is every $1/2/3/7/14$ days, the strategy that averts the highest number of infections per test is 1/2/3/7/14 day universal screening for both the 64% boosted and 18% vaccinated, or the 112 38% boosted and 44% vaccinated cases, averting 11.4/9.9/7.2/6 and 7.4/5.8/3.8/3 infections per 1,000 tests (see Fig. [1\(](#page-16-0)c) and ¹¹³ Fig. $1(d)$), respectively. 114

Impact of Vaccination Status 115

Next, we study the impact of the proportion boosted on the performance of screening strategies, first for the scenario where 116 Omicron is the predominant variant (ω ^{$= 95\%$}). We consider the scenario with total vaccination coverage of 82% (38% 117 boosted, 44% vaccinated), hence with 18% unvaccinated. Under this scenario, universal screening every 1/2/14 days result 118 in 13,803/20,241/23,221 total infections, and 143/357/612 peak daily infections, respectively (see Supplementary Table 5), 119 compared to 8,568/17,327/22,512 total, and $61/222/465$ peak daily infections, respectively, when 64% of the population is boosted. The strategy that averts the highest number of infections per test is daily universal screening, averting 9.3 infections ¹²¹ per 1,000 tests, see Fig. [1\(](#page-16-0)d), whereas the strategy that provides the highest reduction in peak infections per test is screening the 122 unvaccinated every 3 days, which reduces the peak by 1 infection per 1,000 tests (see Fig. [2\(](#page-17-0)d)).

The boosted proportion further impacts hospitalizations (see Supplementary Table 5). With a boosted proportion of ¹²⁴ only 38%, universal screening every 1/2/14 days results in 100/133/145 total hospitalizations, and 12/22/29 peak daily ¹²⁵ hospitalizations, respectively; compared to 61/102/118 total, and 6/14/21 peak daily hospitalizations, respectively, when the boosted proportion is 64% .

When both Delta and Omicron variants are circulating at similar rates ($\omega_{O} = 50\%$, see Supplementary Table 4) and 128 38% of the population is boosted, universal screening every 1/2/14 days results in 1,584/7,478/18,546 infections, and peak ¹²⁹ daily infections of 36/47/219, respectively. If we exclude boosted individuals from screening, 1/2/14-day screening yields 130 $6,341/12,932/19,096$ infections, and peak daily infections of $36/94/229$, respectively.

Customizing the Screening Frequencies 132 Services 132 Services 132 Services 132 Services 132 Services 132 Services

In this section, we study the impact of further customizing the screening frequencies. We first consider that the screening 133 frequency can be customized for each vaccination category included in the screening population, under 82% vaccination ¹³⁴ coverage (64% boosted, 18% vaccinated). When $\omega_0 = 50\%$, the strategy that averts the highest number of infections per test is screening the unvaccinated every 14 days (see Fig. [3\(](#page-18-0)a)), leading to 31.6 infections averted per 1,000 tests (see Supplementary 136 Table 9). The same strategy also provides the highest reduction in peak infections per test (see Fig. [4\(](#page-19-0)a)), i.e., a reduction 137 of 0.9 infections per 1,000 tests. When $\omega_0 = 95\%$, the strategy that averts the highest number of infections per test is daily ¹³⁸ screening of the unvaccinated and vaccinated, and 2-day screening of the boosted (see Fig. [3\(](#page-18-0)b)), resulting in 12.4 infections 139 averted per 1,000 tests, with a 4% improvement compared to the most effective universal screening strategy (i.e., the strategy 140 that screens the entire population with the same screening frequency), see Fig. [3\(](#page-18-0)b) and Supplementary Table 9; whereas the ¹⁴¹ strategy that provides the highest reduction in peak infections per test is screening the unvaccinated only every 3 days (see $_{142}$ Fig. $4(b)$), reducing the peak by 1.09 infections per 1,000 tests. 143

We next consider fully customized screening, where the screening frequency can be customized for each group (faculty 144 versus students) and each vaccination category included in the screening population, under 82% vaccination coverage (64% 145 boosted, 18% vaccinated). When $\omega_0 = 50\%$, the strategy that averts the highest number of infections per test is screening 146 only the unvaccinated students every 14 days (see Fig. [3\(](#page-18-0)c)), leading to 32.5 infections averted per 1,000 tests, with a 2.8% $_{147}$

improvement compared to the most effective strategy that customizes the screening population only. The same strategy also ¹⁴⁸ provides the highest reduction in peak infections per test (see Fig. [4\(](#page-19-0)c)), with a reduction of 0.93 infections per 1,000 tests, $\frac{149}{149}$ which provides a 3.3% improvement compared to the most effective strategy that customizes the screening population only. 150 When ω _O = 95%, the strategy that averts the highest number of infections per test is the daily screening of the unvaccinated and 151 vaccinated students, 2-day screening of the boosted students, and the unvaccinated and vaccinated faculty, and 3-day screening 152 of the boosted faculty, resulting in 12.5 infections averted per 1,000 tests, with a 5% improvement compared to the most ¹⁵³ effective universal screening strategy (see Fig. [3\(](#page-18-0)d)); whereas the strategy that provides the highest reduction in peak infections $_{154}$ per test is screening only the unvaccinated students every 3 days (see Fig. [4\(](#page-19-0)d)), reducing the peak by 1.13 infections per 1,000 ¹⁵⁵ tests and providing a 3.7% improvement compared to the most effective strategy that customizes the screening population only. ¹⁵⁶

Booster Coverage, Vaccine Effectiveness, and Screening Compliance ¹⁵⁷

While screening can be an effective tool for reducing the infection spread, it is uncertain whether aggressive screening, without a high enough booster coverage, would be sufficient for controlling the infection during various phases of the pandemic. We next 159 study the impact of the booster coverage on total infections and total hospitalizations under perfect screening compliance for 160 different Omicron proportions. If $\omega_0 = 50\%$, universal daily screening yields 1,036/894/606/473/295 infections, and 10/10/8/7/5 161 hospitalizations at the end of the semester under booster coverages of $0.2\%/20\%/75\%/82\%$, respectively, see Fig. [5\(](#page-20-0)a), 162 whereas not performing any routine screening during the semester results in 22,445/21,335/19,036/16,919/15,248 infections, 163 and 142/127/103/87/77 hospitalizations at the end of the semester under booster coverages of 0.2%/20%/50%/75%/82%, 164 respectively, see Fig. [5\(](#page-20-0)a). On the other hand, if $\omega_0 = 95\%$, universal daily screening results in 15,965/12,192/5,901/2,382/1,444 ¹⁶⁵ total infections, and 127/93/43/20/13 total hospitalizations for booster coverages of 0.2%/20%/50%/75%/82%, respectively, see ¹⁶⁶ Fig. [5\(](#page-20-0)b), whereas no screening leads to 23,833/23,704/23,338/22,776/22,601 total infections, and 183/164/134/109/101 total 167 hospitalizations under booster coverages of 0.2%/20%/50%/75%/82%, respectively, see Fig. [5\(](#page-20-0)b).

Next, we study the impact of vaccine effectiveness, which is imperfect, decaying over time, and variant-dependent (see 169 Table [3\)](#page-22-1), over several outcomes. When $\omega_0 = 95\%$, even when the entire population is vaccinated (but not boosted) and is screened under perfect compliance, 1/2-day screening leads to 13,755/21,496 total infections, and 70/115 hospitalizations under 171 vaccine effectiveness values reported for Omicron (see Supplementary Table 7). If the vaccine effectiveness for Omicron were ¹⁷² as high as for Delta (see Supplementary Table 8), the same level of mitigation efforts would yield 123/327 infections, and ¹⁷³ $1/2$ hospitalization(s). In this scenario, the number of infections and hospitalizations would be $690/4,079/9,068$, and $4/17/37$, 174 respectively, under 3/7/14-day screening (see Supplementary Table 8). The discrepancy between the two scenarios is less 175 striking, but still significant, when the proportion of Omicron is lower, i.e., $\omega_O = 50\%$, or when the entire population is boosted 176 (see Supplementary Table 8). 177

Recognizing that different campus populations may exhibit different characteristics in their screening compliance, we ¹⁷⁸ further investigate the impact of screening compliance. For 82% vaccination coverage (64% boosted, 18% vaccinated) and ¹⁷⁹ ω ^{ω} = 95%, increasing the screening compliance of universal screening from 75% to 90% reduces the infections from 8,568 to ω

5,563 for daily screening, and from 17,327 to 15,655 for 2-day screening, see Supplementary Table 6. ¹⁸¹

Discussion 182

As new COVID-19 variants emerge, the challenges for effective mitigation of the pandemic in closed communities evolve. 183 Considering the Spring 2022 academic semester and the co-circulating Delta and Omicron variants in this period, the results ¹⁸⁴ from the extended compartmental model in this study suggest that routine screening continues to play a key role in the safe ¹⁸⁵ opening and operation of universities. However, allocating the limited screening resources in the most effective manner ¹⁸⁶ requires extensive planning, considering the specific transmission and disease dynamics of the circulating variants, as well as the vaccination coverage, the imperfect, waning, and variant-dependent immunity from vaccination, and the level of natural 188 immunity in the population.

As expected, the benefits of routine screening increase as the screening coverage is expanded and screening is more frequent. ¹⁹⁰ However, frequent universal screening of the whole campus population may not always be feasible due to the limited testing 191 resources [\[36\]](#page-13-5), and may not even be preferred by the universities due to the well-known testing fatigue [\[37\]](#page-13-6). Thus, designing 192 strategies that yield the highest per-test benefit for various key metrics may provide essential guidelines to universities in establishing effective mitigation policies that are needed for a safe campus environment that is conducive to learning. The ¹⁹⁴ results in this paper demonstrate that the screening strategy that averts the highest number of infections per test depends on the ¹⁹⁵ booster coverage and the characteristics of the predominant variant. Comparing universal strategies with those that customize ¹⁹⁶ the screening population, our results indicate that universal screening is never the most efficient strategy in terms of infections 197 averted per test when both Delta and Omicron variants are in circulation at similar rates, which may represent the U.S. during 198 late December 2021 [\[34\]](#page-13-3). On the other hand, when Omicron is the predominant variant, which has been the case in the U.S. ¹⁹⁹ since early January 2022 [\[35\]](#page-13-4), universal screening does provide the highest per-test reduction in infections. In fact, our findings 200 highlight that the higher the proportion of Omicron and the lower the boosted coverage, the more vaccination status categories ₂₀₁ need to be screened, and at a higher frequency, in order to maximize the infections averted per test. Several factors, including the ₂₀₂ higher reproduction number of, and the lower vaccine efficiency against, Omicron, and the waning vaccine-induced immunity 203 against both variants, contribute to this finding. Furthermore, we observe that as the proportion of Omicron (versus Delta) 204 decreases, the screening frequency that is needed to maximize the efficiency also decreases.

Another key finding is the need for the decision maker to revisit their mitigation objectives as new variants, having different 206 characteristics, emerge. Our results show that when Omicron is the primary circulating variant and screening resources are ₂₀₇ limited, it might be better to focus on minimizing the peak infections, instead of the total infections, where the latter requires 208 aggressive screening that may not be resource-feasible, or practical, for most universities. We show that screening only 209 unvaccinated individuals (that is, customizing the screening population) is the most efficient strategy in terms of the peak 210 infections averted per test under various Omicron proportions and boosted coverage rates. This finding signifies that when ₂₁₁ a variant with a higher reproduction number is the dominant strain, allocating the available testing resources to the most 212

vulnerable provides the most efficient response to the pandemic, by "flattening the curve." We need to emphasize, however, that 213 the most efficient strategy, i.e. the strategy that maximizes infections (or peak infections) averted per-test, may not (and in most 214 scenarios will not) minimize the total number of infections. Since increasing the screening coverage and/or frequency always 215 reduces the total number of infections, universities may need to choose their strategy based on sequentially increasing the ²¹⁶ screening coverage and/or frequency, in the most efficient way, until the expected number of infections is reduced to a tolerable 217 $level.$

There have been significant discrepancies among U.S. colleges and universities regarding routine screening. For example, ²¹⁹ some universities conducted universal screening [\[38\]](#page-13-7), whereas some others customized the screening population based on $_{220}$ vaccination status, but still used the same screening frequency for all the screening population [\[39,](#page-13-8) [40\]](#page-13-9), yet some others did ₂₂₁ switch, at some point, to screening the faculty and students with different screening frequencies. For instance, at the beginning 222 of the Spring semester, Boston University required the faculty to be routinely screened once a week, and the students twice ²²³ a week [\[41\]](#page-13-10). Stanford, on the other hand, required students to be screened weekly but exempted the faculty from routine ₂₂₄ screening at some point in the semester [\[42\]](#page-13-11). Comparing screening strategies with varying degrees of customization, our findings demonstrate that customizing both the screening population and the frequency based on vaccination status may avert ₂₂₆ slightly more infections per test over universal strategies, or strategies that customize the screening population only, especially ₂₂₇ when it is feasible to screen the unvaccinated at higher frequencies, and when both Delta and Omicron are in circulation at 228 similar rates. In this case, the most efficient strategy calls for screening the vaccinated and the boosted less frequently than the unvaccinated, and perhaps not screening the boosted at all. This finding is significant, as it implies that, through customization, ²³⁰ a less aggressive strategy (that screens a smaller portion of the population) can provide higher per-test efficiency than universal $_{231}$ screening. 232

Full customization, which considers both the vaccination status and faculty versus student groups further increases the 233 infections averted per test, over customization based on vaccination status alone. While the improvement is small, the main ²³⁴ message is again that the decision maker can achieve higher per-test benefits with less screening. In particular, when full ²³⁵ customization is considered, the most efficient strategy (for infections averted per test) recommends the faculty to be screened ²³⁶ either less frequently than the students, or not at all. In terms of the peak number of infections averted per test, on the 237 other hand, customizing the screening population already provides a highly efficient strategy, and further customizing the ²³⁸ screening frequency does not offer significant benefits: screening only the unvaccinated remains the dominating strategy. 239 Overall, our results suggest that allowing customization of both the screening population and the frequency based on population ²⁴⁰ characteristics may indeed yield more efficient strategies; equally important is the fact that these customized strategies may also ²⁴¹ lower the required testing resources during the semester. This is because in many cases efficient customized strategies call for 242 some groups to be either tested with very low frequency, or not at all, and this may even reduce the logistical complexity of 243 screening, which was contrary to our initial intuition about customized strategies.

As the vaccine-induced immunity in the population wanes over time and/or new variants, which are more resistant to the

available vaccines, emerge, as was the case at the beginning of 2022, important policy questions arise on whether on-campus ²⁴⁶ screening would be sufficient for infection control, and how these efforts should be adjusted based on the booster coverage at the ₂₄₇ start of the semester. Our results indicate that when both Delta and Omicron are in circulation at similar rates, aiming for both ²⁴⁸ aggressive screening and high levels of booster coverage may be redundant; screening alone may even be able to compensate ²⁴⁹ for a lack of an appropriate booster coverage at the start of the semester. Ideally, integrating moderate levels of booster coverage $_{250}$ and screening can provide a highly effective, yet not aggressive, mitigation effort to keep both the number of infections and 251 hospitalizations under control. When Omicron is the primary circulating variant, however, integrating boosters and screening 252 is key for effective mitigation, as none of these efforts would be sufficient, on its own, for controlling the infection, even when implemented at an aggressive level. Accordingly, our results suggest that both adequate booster coverage and routine 254 screening are essential for a safe opening of university campuses, considering the diminishing vaccine effectiveness over time 255 and new vaccine-resistant variant threats. From a practical perspective, integrated screening and booster efforts work especially 256 well towards creating an academic environment that is conducive to in-person learning, because the system is unlikely to be 257 overwhelmed by a large volume of students and/or faculty missing from the classroom due to an active infection or isolation ²⁵⁸ orders; this can also reduce the potential testing fatigue. 259

Finally, our findings from the sensitivity analyses suggest that if new vaccines are developed with high effectiveness against $_{260}$ emerging variants – at levels comparable to the effectiveness of current vaccines over the Delta variant– it may be possible $_{261}$ to keep both the infections and hospitalizations under control, even with lenient screening, as long as sufficient levels of 262 vaccination/booster coverage are maintained. Our analysis also indicates that, although higher screening compliance leads to ²⁶³ fewer infections, its impact is not substantial, as long as the compliance is kept at a reasonable level (e.g., 75% in our study). ₂₆₄

Methods ²⁶⁵

Study Design and Parameters ²⁶⁶

Our SEIR (Susceptible, Exposed, Infectious, Removed) model extends the compartmental framework in [\[29\]](#page-12-12) in the following ²⁶⁷ ways: We consider a setting where two variants of the virus (Delta and Omicron) might be in circulation simultaneously, and ₂₆₈ model both vaccine-induced immunity and natural immunity (i.e., acquired based on a prior infection), as well as imperfect 269 vaccine effectiveness that depends on both the variant (Delta versus Omicron) and the vaccination status (vaccinated versus ²⁷⁰ boosted). Due to two circulating variants, vaccine effectiveness, infection transmission, and disease characteristics now become 271 conditional on which variant each individual is exposed to. This setting necessitates the modeling of the heterogeneity in 272 the campus population not only in terms of faculty and student groups (indexed by "f, s," respectively), but also based on 273 vaccination status (unvaccinated, vaccinated, and boosted, indexed by "u, v, b," respectively), and the presence or absence of ²⁷⁴ natural immunity. The model simulates the probabilistic transitioning of individuals through different health and vaccination ²⁷⁵ states (compartments), governed by a series of difference equations, group-dependent and/or vaccination status-dependent $_{276}$ transition probabilities. In particular, each individual transitions through *some* subset of the following health states: exposure to ²⁷⁷

the virus, symptom development or asymptomatic infection, recovery and natural immunity (with or without knowledge of $_{278}$ the infection), hospitalization, and death; both disease transmission and disease outcome rates depend on the variant, faculty $_{279}$ versus student group, and vaccination status, see the Supplementary information text for details. We consider the following ²⁸⁰ interventions: 281

- Isolation and face masking: All symptomatic subjects, and positive-testing subjects during routine screening immediately go into isolation. Indoor face masking is required for all subjects.
- Vaccination: We consider two-dose vaccines (i.e., Pfizer and Moderna, which represent around 96% of the vaccines ₂₈₄ administered in the U.S. as of March 13, 2022 [\[43\]](#page-13-12)), and model each subject's vaccination status through the following categories: unvaccinated, vaccinated (fully vaccinated with a two-dose vaccine prior to August 2021), boosted (fully 286 vaccinated, and boosted in January 2022). We do not consider the population that has received only one dose of a two-dose vaccine. Each subject starts the Spring 2022 academic semester in one of these vaccination categories, and ²⁸⁸ remains in the same vaccination status throughout the semester. We do not consider vaccine mandates, but model the ₂₈₉ vaccination coverage of the campus population, that is, the proportion boosted/proportion vaccinated. Because the ²⁹⁰ vaccinated individuals (i.e., without a booster) are assumed to have received their second dose more than four months ²⁹¹ prior to the start of the spring semester, we also model the waning protection from the vaccine, in terms of reduced 292 vaccine effectiveness.
- Routine screening excludes subjects who are symptomatic (symptomatic testing is conducted separately), or who are in $_{294}$ isolation, at the hospital, or who have tested positive for, and recovered from, the infection (i.e., "recovered and known" subjects). We study routine screening, with the specific strategy dictating the *screening population* (i.e., vaccination ²⁹⁶ categories, or faculty versus student groups included in routine screening) and the *screening frequency* of each vaccination category, or faculty/student group. The screening strategy can be *universal* across all groups and vaccination status ²⁹⁸ categories, or *customized*. We study various screening policies, presented below in increasing level of customization, see ²⁹⁹ Table [1.](#page-21-0) 3000 and 300

All screening is conducted via the COVID-19 PCR test, which is the primary test used to detect SARS-CoV-2 [\[44\]](#page-13-13), and subjects 301 receive their test result 8 hours after taking the test, with a positive test result immediately leading to isolation. All false $\frac{302}{202}$ positives are corrected the next day (through additional testing). We assume perfect compliance for all isolation orders and face $\frac{1}{303}$ masking policies, and model imperfect compliance for routine screening. 304

Setting and Parameters: We simulate the infection spread in our hypothetical college of 24,000 (22,500 students and 2,500 $\frac{305}{205}$ faculty members), with 135 students and 9 faculty members (0.6% of each group) having undetected, asymptotic SARS-CoV-2 ³⁰⁶ infection at the outset, and some individuals arriving on campus as vaccinated or boosted. The study period is an 80-day Spring 307 2022 academic semester that starts in January 2022. Table [2](#page-21-1) reports the key parameters, along with corresponding references, ³⁰⁸ and the details are provided in the Supplementary information. $\frac{309}{200}$

A unique feature of our model is that the two variants, Delta and Omicron, can potentially be in circulation simultaneously, ³¹⁰ and parameter ω_0 represents the proportion (in %) of all COVID-19 infections caused by Omicron (1 – ω_0 represents the 311 proportion caused by Delta). The basic reproduction number (*R*0) varies with both groups (faculty versus student) and variant ³¹² (Delta versus Omicron), while vaccine effectiveness against symptom development (ε) and hospitalization (υ) vary with both $\frac{313}{131}$ vaccination status (vaccinated versus boosted) and variant (Delta versus Omicron). To reflect these characteristics in our model, ³¹⁴ we compute the basic reproduction number per group, and vaccine effectiveness per vaccination status, as *weighted averages* 315 of their respective values for each variant, that is, as a function of ω_0 – see Table [3,](#page-22-1) which provides the key parameters, the 316 weighted average formula, and the computed parameters for the $\omega_0 = 50\%$ case, considering a 3:1 ratio between the *R*0 values 317 for Omicron and Delta [\[45,](#page-14-0) [46,](#page-14-1) [47\]](#page-14-2). While these numbers may seem high for the general population, they are more relevant for 318 the college campus setting [\[48\]](#page-14-3). 319

Outcome Measures of Interest: Total infections, hospitalizations, deaths by group (student versus faculty) and by vaccination ³²⁰ status over the 80-day semester; peak daily new infections, peak daily hospitalizations; average number of screening tests per 321 day; number of infections, or peak infections, averted per 1,000 tests compared to the no screening scenario.

Sensitivity Analysis: We conduct various sensitivity analyses through varying the values for: the proportion of all COVID-19 323 infections caused by Omicron (versus Delta), vaccination coverage (proportion boosted/vaccinated), and screening compliance. ³²⁴ We study the effectiveness of various universal and customized screening strategies (see Table [1\)](#page-21-0), obtained by varying the 325 screening frequency(ies) (every 1,2,3,7, 14 days, or no screening) for each vaccination status, see Table [2.](#page-21-1) Different strategies $\frac{326}{2}$ may require different numbers of tests, representing scenarios with different testing capacities or testing kits. $\frac{327}{20}$

Statistical Analysis 328

The compartmental model is coded in C++, and the results are analyzed in Microsoft Excel, through various plots. Our analysis ³²⁹ does not involve any statistical tests, therefore, we do not report statistical significance levels. ³³⁰

Code availability 331

The codes used to generate the results are available at: $\frac{332}{2}$ <https://github.com/mjrabil/Screening-for-safe-opening-of-universities-under-Omicron-and-Delta-variants-of-COVID-19> 333

References ³³⁴

- 1. Nadworny, E. How colleges are dealing with high COVID case counts on campus (Accessed on January 2022). [https:](https://www.npr.org/2022/01/23/1072730869/omicron-college-campuses-covid-outbreaks) [//www.npr.org/2022/01/23/1072730869/omicron-college-campuses-covid-outbreaks.](https://www.npr.org/2022/01/23/1072730869/omicron-college-campuses-covid-outbreaks) ³³⁶
- 2. Johnson, A. G. COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of Delta and Omicron variant emergence—25 US jurisdictions, April 4–December 25, 2021. ³³⁸ *MMWR. Morb. Mortal. Wkly. Rep.* **71** (2022). 339

31. Bouchnita, A., Fox, S. J., Lachmann, M., Herrera-Diestra, G. G. & Meyers, L. A. COVID-19 scenario projections: The 397 It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.05.04.22274667;](https://doi.org/10.1101/2022.05.04.22274667) this version posted May 7, 2022. The copyright holder for this preprint

32. Lee, J. *et al.* Modelling the effects of social distancing, antiviral therapy, and booster shots on mitigating Omicron spread. 399 $(2022).$

emergence of Omicron in the US-January 2022. (2022).

- 33. Tchoumi, S. Y., Rwezaura, H., Diagne, M. L., González-Parra, G. & Tchuenche, J. Impact of infective immigrants on 401 COVID-19 dynamics. *Math. Comput. Appl.* 27, 11 (2022). ⁴⁰²
- 34. Reuters. U.S. CDC estimates Omicron variant to be 58.6% of cases, revises projection (Accessed on April 2022). 403 [https://www.reuters.com/world/us/omicron-estimated-be-586-coronavirus-variants-us-cdc-2021-12-28/.](https://www.reuters.com/world/us/omicron-estimated-be-586-coronavirus-variants-us-cdc-2021-12-28/)
- 35. CDC. Variant proportions (Accessed on April 2022). [https://covid.cdc.gov/covid-data-tracker/#variant-proportions.](https://covid.cdc.gov/covid-data-tracker/##variant-proportions) ⁴⁰⁵

- 2021, by vaccine manufacturer (Accessed on November 2021). [https://www.statista.com/statistics/1198516/](https://www.statista.com/statistics/1198516/covid-19-vaccinations-administered-us-by-company/) ⁴²¹ [covid-19-vaccinations-administered-us-by-company/.](https://www.statista.com/statistics/1198516/covid-19-vaccinations-administered-us-by-company/) 422
- [4](https://my.clevelandclinic.org/health/diagnostics/21462-covid-19-and-pcr-testing)4. Cleveland Clinic. COVID-19 and PCR testing (Accessed on June 2021). [https://my.clevelandclinic.org/health/diagnostics/](https://my.clevelandclinic.org/health/diagnostics/21462-covid-19-and-pcr-testing) 423 [21462-covid-19-and-pcr-testing.](https://my.clevelandclinic.org/health/diagnostics/21462-covid-19-and-pcr-testing) ⁴²⁴

Supplementary Information. 481

Fig. 1 Number of infections averted per 1,000 tests with respect to the screening frequency of the unvaccinated, for various universal and customized screening strategies under various booster and vaccination coverages and Omicron proportions (unvac: unvaccinated, vac: vaccinated)

Fig. 2 Peak number of infections averted per 1,000 tests with respect to the screening frequency of the unvaccinated, for various universal and customized screening strategies under various booster and vaccination coverages and Omicron proportions (unvac: unvaccinated, vac: vaccinated)

■Screen(unvac) ▲Screen(unvac+vac) ●Screen(all) ●Screen(freq custom) ●Screen(full custom)

Fig. 3 Number of infections averted per 1,000 tests with respect to the screening frequency of the unvaccinated, for various customized screening strategies under 64% boosted, 18% vaccinated, 18% unvaccinated, and various Omicron proportions. (a)-(b): Screening is customized based on vaccination status only; the label represents the screening frequency for unvaccinated, vaccinated, boosted. (c)-(d): Screening is customized based on both vaccination status and faculty versus students; the label represents the screening frequency for unvaccinated students, vaccinated students, boosted students, unvaccinated faculty, vaccinated faculty, boosted faculty. ("-" indicates no screening.)

Fig. 4 Peak number of infections averted per 1,000 tests with respect to the screening frequency of the unvaccinated, for various customized screening strategies under 64% boosted, 18% vaccinated, 18% unvaccinated, and various Omicron proportions. (a)-(b): Screening is customized based on vaccination status only; the label represents the screening frequency for unvaccinated, vaccinated, boosted. (c)-(d): Screening is customized based on both vaccination status and faculty versus students; the label represents the screening frequency for unvaccinated students, vaccinated students, boosted students, unvaccinated faculty, vaccinated faculty, boosted faculty. ("-" indicates no screening).

Fig. 5 Total number of infections and hospitalizations with respect to the booster coverage under no screening and universal daily screening under 18% unvaccinated and remaining either boosted or vaccinated, and 100% screening compliance $(\eta = 100\%)$ for: (a) $\omega_0 = 50\%$, (b) $\omega_0 = 95\%$.

Table 1 Description of universal and customized screening strategies.

Table 2 Parameter Values and Ranges for Sensitivity Analysis.

Table 3 Weighted Average Computations for the Basic Reproduction Number and Vaccine Effectiveness Values when the Proportion of Infections Caused by Omicron (Delta) is ω_0 (1 – ω_0)

	Group	Omicron	Delta	Weighted average formula	$\omega_0 = 50\%$ case
Basic reproduction	Students	$3 \times 6 = 18$	-6	$RO_{(k,s)}^{\omega_O} = 6 \times (1 - \omega_O) + 18 \times \omega_O$	$RO_{(k,s)}^{\omega_0=50\%} = 12$
number $(R0)$, $k \in \{u, v, b\}$	Faculty	$3 \times 3.2 = 9.6$	3.2	$RO_{(k-f)}^{\omega_0} = 3.2 \times (1 - \omega_0) + 9.6 \times \omega_0$	$RO_{(k,f)}^{\omega_0=50\%}=6.4$
Vaccine effectiveness	Vaccinated	33%	80%	$\varepsilon_{v}^{\omega_{O}} = 80\% \times (1 - \omega_{O}) + 33\% \times \omega_{O}$	$\epsilon_v^{\omega_0=50\%} = 56.5\%$
against infection (ε)	Boosted	69.4%	86.7%	$\varepsilon_b^{\omega_O} = 86.7\% \times (1 - \omega_O) + 69.4\% \times \omega_O$	$\varepsilon_h^{\omega_0 = 50\%} = 78.05\%$
Vaccine effectiveness	Vaccinated	70%	91.7%	$v_v^{\omega_0} = 91.7\% \times (1 - \omega_0) + 70\% \times \omega_0$	$\overline{v_v^{\omega_0=50\%}=80.85\%}$
against hospitalization (v)	Boosted	93%	97.5%	$v_b^{\omega_0} = 97.5\% \times (1 - \omega_0) + 93\% \times \omega_0$	$v_{\nu}^{\omega_0=50\%}=95.25\%$